



## RESEARCH ARTICLE

# Application of the intervention Complexity Assessment Tool for Systematic Reviews within a Cochrane review: an illustrative case study [version 1; peer review: 3 approved]

Cathal A. Cadogan <sup>1</sup>, Audrey Rankin<sup>2</sup>, Simon Lewin <sup>3,4</sup>, Carmel M. Hughes<sup>2</sup>

<sup>1</sup>School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Ireland

<sup>2</sup>School of Pharmacy, Queen's University Belfast, Belfast, UK

<sup>3</sup>Division of Health Services, Norwegian Institute of Public Health, Oslo, Norway

<sup>4</sup>Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa

**v1** **First published:** 01 Jun 2020, 3:31  
<https://doi.org/10.12688/hrbopenres.13044.1>  
**Latest published:** 01 Jun 2020, 3:31  
<https://doi.org/10.12688/hrbopenres.13044.1>

## Abstract

**Background:** The intervention Complexity Assessment Tool for Systematic Reviews (iCAT\_SR) has been developed to facilitate detailed assessments of intervention complexity in systematic reviews. Worked examples of the tool's application are needed to promote its use and refinement. The aim of this case study was to apply the iCAT\_SR to a subset of 20 studies included in a Cochrane review of interventions aimed at improving appropriate polypharmacy in older people.

**Methods:** Interventions were assessed independently by two authors using the six core iCAT\_SR dimensions: (1) 'Target organisational levels/categories'; (2) 'Target behaviour/actions'; (3) 'Active intervention components'; (4) 'Degree of tailoring'; (5) 'Level of skill required by intervention deliverers'; (6) 'Level of skill required by intervention recipients'. Attempts were made to apply four optional dimensions: 'Interaction between intervention components'; 'Context/setting'; 'Recipient/provider factors'; 'Nature of causal pathway'. Inter-rater reliability was assessed using Cohen's Kappa coefficient. Disagreements were resolved by consensus discussion. The findings are presented narratively.

**Results:** Assessments involving the core iCAT\_SR dimensions showed limited consistency in intervention complexity across included studies, even when categorised according to clinical setting. Interventions were delivered across various organisational levels and categories (i.e. healthcare professionals and patients) and typically comprised multiple components. Intermediate skill levels were required by those delivering and receiving the interventions across all studies. A lack of detail in study reports precluded application of the iCAT\_SR's optional dimensions. The inter-rater reliability was substantial (Cohen's Kappa = 0.75)

**Conclusions:** This study describes the application of the iCAT\_SR to studies included in a Cochrane systematic review. Future intervention studies need to ensure more detailed reporting of interventions, context and the causal pathways underlying intervention effects to allow a more holistic

## Open Peer Review

Reviewer Status

	Invited Reviewers		
	1	2	3
<b>version 1</b>			
01 Jun 2020	<a href="#">report</a>	<a href="#">report</a>	<a href="#">report</a>

- 1 **Livia Puljak** , Catholic University of Croatia, Zagreb, Croatia
- 2 **Marie Gaarder**, International Initiative for Impact Evaluation, Oslo, Norway
- 3 **Daniel Cury Ribeiro** , University of Otago, Dunedin, New Zealand

Any reports and responses or comments on the article can be found at the end of the article.

understanding of intervention complexity and facilitate replication in other settings. The experience gained has helped to refine the original guidance document relating to the application of iCAT\_SR.

### Keywords

intervention complexity, intervention complexity assessment tool, iCAT\_SR, systematic review, evidence synthesis, complex interventions, polypharmacy, older people

**Corresponding author:** Cathal A. Cadogan ([cathalcadogan@rcsi.ie](mailto:cathalcadogan@rcsi.ie))

**Author roles:** **Cadogan CA:** Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Visualization, Writing – Original Draft Preparation; **Rankin A:** Conceptualization, Formal Analysis, Investigation, Methodology, Visualization, Writing – Review & Editing; **Lewin S:** Conceptualization, Formal Analysis, Funding Acquisition, Methodology, Visualization, Writing – Review & Editing; **Hughes CM:** Conceptualization, Funding Acquisition, Methodology, Writing – Review & Editing

**Competing interests:** No competing interests were disclosed.

**Grant information:** Health Research Board [HRC/2014/1] (to A.R.). C.A.C. was supported in undertaking this research by a Charlemont Award from the Royal Irish Academy. S.L. also receives funding from the South African Medical Research Council.

*The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.*

**Copyright:** © 2020 Cadogan CA *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**How to cite this article:** Cadogan CA, Rankin A, Lewin S and Hughes CM. **Application of the intervention Complexity Assessment Tool for Systematic Reviews within a Cochrane review: an illustrative case study [version 1; peer review: 3 approved]** HRB Open Research 2020, 3:31 <https://doi.org/10.12688/hrbopenres.13044.1>

**First published:** 01 Jun 2020, 3:31 <https://doi.org/10.12688/hrbopenres.13044.1>

## Introduction

Several definitions of the term ‘*complex intervention*’ exist in the literature. For example, the UK Medical Research Council has defined ‘*complex interventions*’ as “*interventions that contain several interacting components*” while recognising that there are multiple dimensions of complexity (e.g. the number of intervention components, interactions between components, target behaviours, target groups or organisational levels, outcomes and degree of tailoring permitted)<sup>1</sup>. It is recognised that a broader understanding of the term ‘*complex intervention*’ is required. For example, Moore *et al.* contend that “*all interventions are complex, but some are more complex than others*” and that “*rather than an absolute property of new components, intervention complexity can therefore be understood as a relative construct, linked to usual practice within the system, and encompassing challenges associated with disrupting and replacing often entrenched ways of working*”<sup>2</sup>. Petticrew has hypothesised that there is in fact no true categorisation of interventions as ‘simple’ or ‘complex’, and that the concepts of simplicity and complexity are instead pragmatic perspectives adopted by researchers to help describe and understand the interventions being evaluated<sup>3</sup>.

Interventions targeting key healthcare issues, such as multimorbidity and the use of multiple medications (i.e. polypharmacy) in older people, are often complex in that the interventions typically involve multiple components<sup>4,5</sup>. However, this broad categorisation of interventions based on their components limits our potential to systematically compare interventions and their effects. Without a more detailed exploration of intervention complexity, it is difficult to determine if varying degrees of complexity impact on intervention effectiveness. The intervention Complexity Assessment Tool for Systematic Reviews (iCAT\_SR) has been developed to facilitate a more detailed and systematic assessment of intervention complexity in systematic reviews<sup>6</sup>. The tool’s development process involved a series of steps which included: drafting a list of possible intervention complexity dimensions based on a review of relevant literature; development of provisional definitions for these dimensions; discussion and consensus workshops with trialists and implementation scientists to refine and agree on the tool’s core dimensions and definitions; preliminary testing of draft versions of the tool against published intervention reports; development of a finalised version of the tool and guidance document to assist with its application following further testing and refinement. Rather than providing a definitive definition of intervention complexity, the tool focuses on dimensions of complexity that can be assessed when evaluating interventions as part of a systematic review. The first version of the tool (iCAT\_SR version 1.0) comprises six core dimensions and four additional dimensions that are considered to be optional, as they may not be relevant to all interventions (Table 1). Within each dimension, there are different levels of complexity assessments. A detailed elaboration on the tool’s dimensions is available from Lewin *et al.*<sup>6</sup> and the accompanying guidance document<sup>7</sup>.

Application of iCAT\_SR in the context of systematic reviews may ultimately help researchers to consider dimensions of

intervention complexity that have previously been overlooked so as to guide the pooling of studies for analysis and enhance the interpretation of review findings<sup>6</sup>. Worked examples of the tool’s application are needed to promote its use and refinement. However, to date, references to the application of iCAT\_SR primarily relate to protocols of ongoing systematic reviews<sup>8–10</sup>.

This case study is a proof-of-concept of the potential application of iCAT\_SR to studies included in a Cochrane review. The aim was to apply the intervention Complexity Assessment Tool for Systematic Reviews (iCAT\_SR) to a subset of interventions included in a Cochrane systematic review of interventions aimed at improving appropriate polypharmacy in older people<sup>11</sup>. In this paper, we report on our experiences of applying iCAT\_SR to included studies and outline potential refinements to the tool to facilitate its future application as part of systematic reviews.

## Methods

A convenience sample of intervention studies included in a recent update of a Cochrane review of interventions to improve appropriate polypharmacy in older people<sup>12</sup> was assessed using the iCAT\_SR<sup>6</sup>. The sample comprised all 20 included studies following the first round of database searches conducted as part of the review’s update. The review followed the Cochrane Collaboration’s methodology for updates of reviews. Key information relating to the review’s PICO (Population, Intervention, Comparison, Outcomes) is summarised in Table 2 and detailed information on all aspects of the methods used is available in the published review<sup>11</sup>.

**Assessment of intervention complexity using the iCAT\_SR**  
Assessment of intervention complexity was performed independently by two reviewers (CC, AR) using the iCAT\_SR (Table 1). Both reviewers are experienced health services researchers who led on the most recent update of the Cochrane review and, therefore, had in-depth knowledge of the included studies. In order to mitigate against a lack of detailed reporting in published study reports, study authors were emailed to request further information (e.g. intervention protocols).

For each intervention, key information was extracted using a purposefully developed data extraction form (*Extended data File 1*<sup>13</sup>). In completing the assessments, the iCAT\_SR guidance document<sup>7</sup> was used as the coding manual. For each complexity dimension, the assessment level and criteria detailed in the guidance document were applied. The coders identified relevant information from the description of the intervention under each assessment dimension, assigned a complexity rating and provided support for their assessments. Notes were taken during the coding process on any issues with applying the iCAT\_SR based on the assessment levels/criteria and any refinements that were needed for the guidance document.

To aid graphical presentation of results, assessment levels across each dimension were categorised as ‘high’, ‘intermediate’, ‘low’ or ‘unclear’ using the definitions in the published tool (Table 1). Cohen’s Kappa coefficient was used to assess inter-rater

**Table 1. Overview of iCAT\_SR dimensions (version 1.0).**

<b>Core dimensions</b>	<b>Assessment categories*</b>
1. Organisational levels and categories targeted by the intervention	I. Multi-level II. Multi-category III. Single category
2. Behaviour or actions of intervention recipients or participants to which the intervention is directed	I. Multi-target II. Dual target III. Single target IV. Varies
3. Active components included in the intervention, in relation to the comparison	I. More than one component and delivered as a bundle II. More than one component III. One component IV. Varies
4. The degree of tailoring intended or flexibility permitted across sites or individuals in applying or implementing the intervention	I. Highly tailored/flexible II. Moderately tailored/flexible III. Inflexible IV. Varies
5. The level of skill required by those delivering the intervention in order to meet the intervention objectives	I. High level skills II. Intermediate level skills III. Basic skills IV. Varies
6. The level of skill required for the targeted behaviour when entering the included studies by those receiving the intervention, in order to meet the intervention objectives	I. High level skills II. Intermediate level skills III. Basic skills IV. Varies
<b>Optional dimensions</b>	<b>Assessment categories*</b>
7. The degree of interaction between intervention components, including the independence/interdependence of intervention components	I. High level interaction II. Moderate interaction III. Independent IV. Varies V. Unclear/unable to assess
8. The degree to which the effects of the intervention are dependent on the context or setting in which it is implemented	I. Highly context dependent II. Moderately context dependent III. Independent of context IV. Varies V. Unclear/unable to assess
9. The degree to which the effects of the intervention are changed by recipient or provider factors	I. Highly dependent on individual-level factors II. Moderately dependent on individual-level factors III. Largely independent of individual-level factors IV. Varies V. Unclear/unable to assess
10. The nature of the causal pathway between the intervention and the outcome it is intended to effect	I. Pathway variable, long II. Pathway linear, long III. Pathway linear, short IV. Varies V. Unclear/unable to assess

\*Categorisation of assessment levels: I = high; II = intermediate; III = low; IV = varies; V = unclear/unable to assess

reliability between the two reviewers ( $\leq 0.2$  = poor agreement, 0.21–0.40 = fair agreement, 0.51–0.6 = moderate agreement, 0.61–0.8 = substantial agreement, 0.81–1.00 = good agreement)<sup>14</sup>. Any disagreements were resolved by discussion with another member of the research team (SL) who led on the development of iCAT\_SR<sup>6</sup>.

## Results

The characteristics of the subset of 20 studies<sup>15–34</sup> to which the iCAT\_SR was applied are summarised in *Extended data File 2*<sup>13</sup>. Briefly, these studies consisted of 12 randomised controlled trials (RCTs), six cluster RCTs and two controlled before-after studies. In total, 25,674 older patients were

**Table 2. Summary of key inclusion criteria for Cochrane review of interventions to improve appropriate polypharmacy in older people.**

Study features	Key inclusion criteria
Population	Older people ( $\geq 65$ years) in any healthcare setting with more than one long-term medical condition and receiving polypharmacy ( $\geq 4$ medications)
Intervention	All types of interventions that aimed to improve appropriate polypharmacy in older people in any healthcare setting were eligible for inclusion provided that a validated tool was used to assess the appropriateness of prescribing  Studies using expert opinion alone to assess the appropriateness of prescribing were excluded
Comparison	Interventions had to be compared against usual care as defined by the study (except for interrupted time series studies)
Outcomes	<u>Primary outcomes</u> <ol style="list-style-type: none"> <li>I. Medication appropriateness (as measured by an implicit tool, such as the Medication Appropriateness Index<sup>35</sup>)</li> <li>II. Potentially inappropriate medications (as defined by a validated explicit tool such as STOPP (Screening Tool of Older People's Prescriptions) criteria<sup>36</sup>) which could consist of the number of potentially inappropriate medications and/or the proportion of patients with one or more potentially inappropriate medications</li> <li>III. Potential prescribing omissions (as defined by a validated explicit tool such as START (Screening Tool to Alert to Right Treatment) criteria<sup>36</sup>) which could consist of the number of potential prescribing omissions and/or the proportion of patients with one or more potential prescribing omissions</li> <li>IV. Hospital admissions (which included all-cause hospital admissions and unplanned hospital readmissions)</li> </ol> <u>Secondary outcomes</u> <ol style="list-style-type: none"> <li>V. Medication-related problems (e.g. adverse drug reactions, drug-drug interactions)</li> <li>VI. Adherence to medication</li> <li>VII. Quality of life</li> </ol>
Study designs	Randomised controlled trials (RCTs), cluster RCTs, non-randomised trials, controlled before-and-after studies and interrupted time series

involved, the majority of whom were female (65.8% in intervention groups, 65.6% in control groups). On average, patients were 77.2 years old and receiving nine medicines at baseline. The studies were conducted in three types of settings: hospitals (outpatient clinics, hospital/care home interface, inpatient settings), primary care and nursing homes/residential care settings. The studies were carried out in ten countries: Australia (three studies), Belgium (two studies), Canada (two studies), Finland (one study), Germany (two studies), Ireland (two studies), Israel (one study), Italy (one study), Spain (one study) and the USA (five studies).

### Interventions

Overall, 19 studies examined pharmaceutical care-based interventions across various settings. Pharmaceutical care reflects a systematic approach to the provision of care that ensures patients receive the correct medication, at appropriate doses, for appropriate indications. It typically involves medication reviews by pharmacists in collaboration with physicians, patients and carers<sup>37</sup>. One study<sup>29</sup> evaluated a single component intervention in the form of computerised decision support that was provided

to general practitioners (GPs) in their own practices. Further details about the interventions are summarised in *Extended data File 2*<sup>13</sup>.

### iCAT\_SR complexity assessments

Overviews of the intervention complexity assessments across the six core dimensions for the 20 studies are displayed in *Table 3*. A brief outline of the assessments under each of the iCAT\_SR dimensions is provided in the subsections below. A detailed breakdown of individual iCAT\_SR assessments for each study (including justifications for assigned ratings) is provided in *Extended data File 3*<sup>13</sup>. The inter-rater reliability was substantial (Cohen's Kappa = 0.75)<sup>14</sup>.

Efforts were made to apply the iCAT\_SR optional dimensions. However, a lack of detailed information in the study reports made it difficult to apply the iCAT\_SR's optional dimensions consistently across the included studies. For example, none of the included studies reported on the interaction between intervention components or the nature of the causal pathway between intervention components and outcomes.

**Table 3. Assessments of core iCAT\_SR dimensions for individual studies of interventions aimed at improving appropriate polypharmacy in older people.**

Study ID grouped by setting	iCAT_SR assessment dimension					
	Organisational levels/categories	Behaviour or actions	Active components	Level of tailoring	Skill level required by those delivering intervention	Skill level required by those receiving intervention
<b>Community</b>						
Clyne 2015	High	High	High	Intermediate	Intermediate	Intermediate
Tamblyn 2003	Low	High	Low	Intermediate	Intermediate	Intermediate
Taylor 2003	High	High	High	Intermediate	Intermediate	Intermediate
<b>Hospital</b>						
Basger 2015	High	High	High	Intermediate	Intermediate	Intermediate
Bucci 2003	High	High	Intermediate	High	Intermediate	Intermediate
Crotty 2004b	Intermediate	High	High	High	Intermediate	Intermediate
Dalleur 2014	Low	High	High	Intermediate	Intermediate	Intermediate
Franchi 2016	Low	High	High	Low	Intermediate	Intermediate
Gallagher 2011	Low	High	High	Intermediate	Intermediate	Intermediate
Hanlon 1996	High	High	High	High	Intermediate	Intermediate
Michalek 2014	Low	High	High	High	Intermediate	Intermediate
Schmader 2004	High	High	High	High	Intermediate	Intermediate
Spinewine 2007	High	High	High	High	Intermediate	Intermediate
Wehling 2016	Low	High	High	High	Intermediate	Intermediate
<b>Residential care</b>						
Crotty 2004a	Intermediate	High	High	High	Intermediate	Intermediate
Frankenthal 2014	Low	High	High	Intermediate	Intermediate	Intermediate
Garcia-Gollarte 2014	Low	High	High	Low	Intermediate	Intermediate
Pitkala 2014	Intermediate	High	High	Low	Intermediate	Intermediate
Trygstad 2005	Low	High	High	Intermediate	Intermediate	Intermediate
Trygstad 2009	Low	High	Intermediate	Intermediate	Intermediate	Intermediate

#### Organisational levels/categories

Half of the interventions targeted a single category of individuals (n=10, low level complexity rating), comprising healthcare professionals or patients. In the other studies, interventions were categorised as multi-level (n=7, high level complexity rating) when the interventions typically targeted both patients and healthcare professionals, or multi-category (n=3, intermediate level complexity rating), where multiple groups of healthcare professionals (i.e. GPs, pharmacists, nurses) within the same setting were targeted.

#### Target behaviours/actions and active components

All of the interventions were deemed to be multi-target (high level complexity rating) in that they involved multiple target behaviours/actions. In all studies, this included appropriate prescribing for older patients receiving polypharmacy and the component behaviours/actions (e.g. reviewing prescriptions, implementing prescribing changes).

With the exception of one study, all of the interventions involved more than one component. Tamblyn *et al.* evaluated an inter-

vention comprising computerised decision support which was categorised as a single component intervention (low level complexity rating)<sup>29</sup>. The interventions involving more than one component were further subcategorised according to whether there was a defined order to the delivery of intervention components. There were 17 interventions delivered as a bundle (as opposed to an intervention package) as there was an order/sequence to the delivery of the interventions components (high level complexity rating). This was evident in a number of the hospital-based studies that involved the application of prescribing criteria to identify potentially inappropriate medications, which were then communicated to relevant members of a patient's medical team and prescribing changes subsequently implemented<sup>19,22</sup>.

In two studies<sup>16,32</sup>, there was no apparent order to the delivery of intervention components and the interventions were therefore categorised as packages as opposed to intervention bundles (intermediate level complexity rating). For example, the multi-level intervention evaluated by Bucci *et al.*<sup>16</sup> targeted both patients and prescribers. Directive guidance was provided to patients with the intention of improving medication adherence, while prescribers were targeted by the pharmacist-led intervention to improve the appropriateness of medication prescribing. However, the order in which the intervention components were delivered was not explicitly stated and it was not clear if the patient-targeted component came, or needed to come, before or after the prescriber-targeted component.

#### Level of tailoring

Eight interventions were categorised as highly tailored/flexible (high level complexity rating). These interventions typically involved the application of implicit tools (e.g. Medication Appropriateness Index<sup>35</sup>) in assessing the appropriateness of patients' medications. Given the judgement-based nature of these types of tools, a higher degree of tailoring/flexibility would have been permitted when being applied at the individual patient level.

Nine interventions were categorised as moderately tailored/flexible (intermediate level complexity rating). These interventions typically involved the application of explicit tools in assessing the appropriateness of patients' medications (e.g. STOPP/START<sup>36</sup>, Beers' criteria<sup>38</sup>). The rationale for rating explicit tools as moderately flexible was that while they consist of criteria relating to potentially inappropriate prescribing in older people, it is at clinicians' discretion as to the whether the criteria are applicable to individual patients. Therefore, although these tools consist of pre-specified criteria, there is a degree of flexibility in terms of their application at the individual patient level.

The three interventions categorised as inflexible (low level complexity rating) involved education and training for health-care professionals<sup>20,23,26</sup>. In contrast to the studies involving prescribing tools, the intention with these interventions would be to deliver a defined and clearly specified learning activity which would have arguably less flexibility once it had been developed.

#### Skill level required by those delivering and receiving interventions

For all 20 studies, assessments of the level of skill for those delivering and receiving interventions were rated as intermediate (intermediate level complexity rating). In both instances, the target behaviours/actions related to appropriate prescribing for older people. This was considered to be within the scope of normal practice of those involved in delivering and/or receiving the interventions (e.g. physicians working in geriatric hospital wards reviewing older patients' medications), such that no specialisation was deemed to have been required.

#### Discussion

This study provides the first detailed overview of the application of the iCAT\_SR<sup>6</sup>. The experience gained (discussed below) may assist with the tool's use in systematic reviews in other clinical areas. The findings also demonstrate that interventions categorised as 'multifaceted' (comprising two or more components) in previous iterations of this review<sup>4,39</sup> varied in complexity using the tool's core assessment dimensions. This highlights how broad terms, such as uni-faceted and multifaceted, do not adequately describe the scope of intervention complexity and further illustrates the importance of considering a range of dimensions of complexity using a tool such as iCAT\_SR.

#### Experience in applying iCAT\_SR

Despite detailed available guidance on the tool's application<sup>7</sup>, this work was not without challenges. For example, time needed to be allocated to upskilling the review team on the iCAT\_SR and then applying it to the interventions. Hence, this initial coding exercise focused on a subset of studies identified following the initial round of searches for the most recent update of this Cochrane review<sup>12</sup>. Therefore, this work is not intended as a definitive assessment of intervention complexity in this field of research but as proof of concept of the iCAT\_SR's application.

The inter-rater reliability was substantial. Most of the observed variation between the individual rater assessments was primarily attributable to differences in the interpretation of the two skill-related dimensions (i.e. skill level required by those delivering or receiving the intervention) between the coders and whether they represented intermediate or high level skills. In assessing these dimensions, it is important to consider the baseline level of skill that would be expected of the individual(s) delivering or receiving the intervention and to note whether the study reports on the skill level required or possessed. For instance, if a study reports that individuals delivering an intervention were highly skilled and qualified/experienced, this does not necessarily mean that this level of skill/experience was required to deliver the intervention. Assessments based on the reported level of skill/experience as opposed to the required skill level could result in the complexity level assessment for this dimension being overestimated.

For the purpose of this coding exercise, appropriate prescribing for older people was deemed to be within the scope of practice of those involved in delivering and/or receiving the interventions (e.g. physicians working in geriatric hospital wards reviewing older patients' medications), such that no specialisation was considered necessary. Consequently, all skills-related assessments were rated as intermediate. Assessments of skill level requirements should ideally be based on details of prior training. However, this may not always be explicitly outlined in study reports, in which case a judgement is required based on expected baseline skill level. In such cases, we recommend specifying *a priori* how decisions will be made between each of the assessments levels.

An additional challenge in applying the tool's coding manual related to the assessment of the target behaviour (i.e. prescribing of appropriate polypharmacy) across included studies. The more precisely a behaviour is defined, the greater the specificity of the barriers and facilitators identified (e.g. reducing overprescribing of benzodiazepines, a commonly identified class of potentially inappropriate medications in older people); however, cases exist where it is not possible to isolate and target one behaviour for change, particularly where multiple interdependent behaviours exist (e.g. ensuring prescribing of appropriate polypharmacy for older people)<sup>40,41</sup>. Unless explicitly outlined at the outset for any given intervention, compiling an exhaustive list of these interdependent behaviours (also referred to as sub-behaviours) is practically impossible<sup>41</sup>. This was the case with regard to the prescribing of appropriate polypharmacy – although these interventions typically involved medication reviews and implementation of prescribing changes, this represented an over-simplification of the key behaviours/actions. As such, the intricacies of the nursing home-based interventions that involved multi-disciplinary case conferences was not adequately captured<sup>18,34</sup>. Consequently, the target behaviour across all included studies was categorised as multi-target. However, this detracted from the potential of this core complexity dimension to discriminate between interventions. Reporting on the behaviours and actions taken as part of interventions more explicitly in future research may help in discriminating more clearly between interventions. In the interim, future research involving application of iCAT\_SR may look to prioritise key expected behaviours or actions across interventions<sup>40</sup>.

Finally, a lack of detailed reporting and the absence of an explicit theoretical underpinning across the interventions precluded consistent application of the iCAT\_SR's optional dimensions. These are both well recognised issues with the existing literature<sup>42-47</sup>. Consequently, assessments were largely based on the reported interventions without detailed consideration of the context/settings in which they were delivered, the interaction between intervention components and the nature of the causal pathway between intervention components and outcomes. Addressing these widely recognised issues through application of relevant reporting guidelines and checklists<sup>48-51</sup>, as well as operationalisation of appropriate theory in future research, would

help to ensure more consistent application of the tool's optional dimensions. This could enhance the tool's capability of discriminating between interventions and offering plausible explanations for sources of heterogeneity between studies. Reporting on interactions between intervention components and the nature of the causal pathways underlying intervention effects would enhance our understanding of not just what interventions work, but also in understanding what happens when they are implemented<sup>52</sup>. This could ultimately enable systematic reviews of interventions to extend beyond assessing whether interventions are effective or not, to interrogating the role of different intervention components, and exploring how, why and for whom the intervention works, and under what circumstances<sup>53</sup>.

### Interpreting iCAT\_SR assessments

The iCAT\_SR assessments for individual studies were consistent across three dimensions which related to behaviour and skills. This was to some extent expected as the interventions focussed on improving appropriate prescribing and were delivered by clinicians involved in the care of older patients. For the remaining dimensions, there was no consistent pattern for intervention complexity assessments across included studies even when categorised according to setting. We had considered the application of a scoring system to the iCAT\_SR assessments as part of this work. However, we were unable to establish a firm evidence base on which to base one.

### Refinements to iCAT\_SR

The experience gained from applying the iCAT\_SR has identified two potential refinements to the tool and the associated guidance document<sup>6</sup>. Firstly, the assessment dimensions in the original tool have been re-ordered to enable a more logical sequence of conceptualisation and application (i.e. starting with 'Organisational levels/categories' and progressing to 'Behaviour or actions', 'Active components', etc.). Secondly, additional examples have been incorporated to supplement the existing ones which were largely directed towards health system and public health interventions<sup>7</sup>. These may assist with the tool's application to systematic reviews in other clinical areas. A revised version will be published on the Cochrane Collaboration's website at a later date.

### Relationship to other work in the field

A recent systematic review of interventions to promote active transport to school in children has also applied the iCAT\_SR<sup>54</sup>. The authors assigned arbitrary scores to each assessment dimension to calculate a global complexity score for each study and then assessed if there was a correlation between intervention complexity and effectiveness. Considerable variation was reported in global complexity scores across included studies and no correlation was detected between intervention complexity and effectiveness. However, the review authors noted the need for more robust methods of evaluating the relationship between intervention complexity and effectiveness.

A previous overview of systematic reviews seeking to compare the effectiveness of multifaceted interventions and uni-faceted



interventions in changing healthcare professionals' behaviour found no compelling evidence that the former were more effective<sup>55</sup>. The current study allowed limited comparison of uni-faceted interventions and multifaceted interventions. The computerised decision support-based intervention evaluated by Tamblin *et al.*<sup>29</sup> that was previously described in the review as uni-faceted<sup>4</sup> showed comparable assessments across a number of complexity dimensions to other interventions that were categorised as multi-faceted. This simple dichotomy of interventions according to the presence of one component or more than one component may overlook critical dimensions of complexity that impact on effectiveness. This lends support to the view that it is difficult and probably not useful to create a simple definition of a complex intervention<sup>6,56</sup>. Therefore, it may be more appropriate to define complexity in terms of intervention characteristics as opposed to the number of intervention components alone. For example, Guise *et al.*<sup>57</sup> have defined complex interventions based on key characteristics that extend beyond the intervention and components and encompass a range of other dimensions including pathway complexity, population complexity, implementation complexity and contextual complexity. It is important to recognise that complexity is not merely a characteristic of the interventions themselves but also a feature of the systems (i.e. context, setting) in which they are delivered<sup>58</sup>.

#### Implications for use in future reviews

The application of the iCAT\_SR was a useful exercise, as it allowed dimensions of complexity to be assessed systematically across included studies. However, the value of including iCAT\_SR assessments in future updates of the review is currently unclear, in relation to the additional work involved. Further work is needed to determine if application of the iCAT\_SR can help to interpret whether varying levels of complexity impact on intervention effectiveness. Systematic reviews involving larger numbers of studies with data that can be pooled in meta-analyses may allow more detailed analysis of relationships between iCAT\_SR assessments and intervention effect sizes using appropriate statistical techniques such as meta-regression. It is important that other systematic reviews focusing on other intervention areas apply the iCAT\_SR and report on both the findings and experiences of using the tool. This will help in continuing to refine the tool and establishing methods for

determining whether varying levels of complexity impact on intervention effectiveness.

#### Conclusion

This study reports on the application of the iCAT\_SR to a subset of studies included in a Cochrane review of interventions to improve appropriate polypharmacy in older people. The findings show that categorisation of interventions as multi-faceted or unifaceted without a more detailed assessment of other dimensions of complexity is a potential oversimplification as it not necessarily the case that interventions with fewer components are less complex across all relevant complexity dimensions. Future research needs to ensure more detailed reporting of interventions, context and the nature of the causal pathways underlying intervention effects to allow a more holistic understanding of intervention complexity. This could assist in ensuring more informative descriptions of interventions and the context in which they are delivered, and ultimately contribute to both understanding the effects of these interventions and facilitating replication in other settings.

#### Data availability

##### Underlying data

All data underlying the results are available as part of the article and no additional source data are required.

##### Extended data

Open Science Framework: Application of the intervention Complexity Assessment Tool for Systematic Reviews (iCAT\_SR) within a Cochrane review. <https://doi.org/10.17605/OSF.IO/N3KW2><sup>13</sup>.

This project contains the following extended data:

- File 1: Data extraction form
- File 2: Cochrane review summary findings
- File 3: iCAT\_SR assessments for individual studies

Data are available under the terms of the [Creative Commons Zero “No rights reserved” data waiver](#) (CC0 1.0 Public domain dedication).

#### References

1. Medical Research Council: **Developing and evaluating complex interventions: new guidance**. In: London: United Kingdom: Medical Research Council; 2008; Accessed: 01/05/20. [Reference Source](#)
2. Moore G, Evans R, Hawkins J, *et al.*: **All interventions are complex, but some are more complex than others: using iCAT\_SR to assess complexity**. *Cochrane Database Syst Rev*. 2017; 7: ED000122. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Petticrew M: **When are complex interventions ‘complex’? When are simple interventions ‘simple’?** *Eur J Public Health*. 2011; 21(4): 397–8. [PubMed Abstract](#) | [Publisher Full Text](#)
4. Patterson SM, Cadogan CA, Kerse N, *et al.*: **Interventions to improve the appropriate use of polypharmacy for older people**. *Cochrane Database Syst Rev*. 2014; (10): CD008165. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Smith SM, Wallace E, O’Dowd T, *et al.*: **Interventions for improving outcomes in patients with multimorbidity in primary care and community settings**. *Cochrane Database Syst Rev*. 2016; 3(3): CD006560. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Lewin S, Hendry M, Chandler J, *et al.*: **Assessing the complexity of interventions within systematic reviews: development, content and use of a new tool (iCAT\_SR)**. *BMC Med Res Methodol*. 2017; 17(1): 76. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Lewin S, Hendry M, Chandler J, *et al.*: **Guidance for using the iCAT\_SR:**

**Intervention Complexity Assessment Tool for Systematic Reviews (Version 1.0).** Accessed 01.05.20.

[Reference Source](#)

8. Chung Y, Garden FL, Marks GB, *et al.*: **Non-invasive positive airway pressure therapy for obesity hypoventilation syndrome in adults (Protocol).** *Cochrane Database Syst Rev.* 2018; 3: CD012976.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
9. Ribeiro DC, Abbott JH, Sharma S, *et al.*: **Process evaluation of complex interventions tested in randomised controlled trials in musculoskeletal disorders: a systematic review protocol.** *BMJ Open.* 2019; 9(5): e028160.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
10. Alghamdi SM, Janaudis-Ferreira T, Alhasani R, *et al.*: **Acceptance, adherence and dropout rates of individuals with COPD approached in telehealth interventions: a protocol for systematic review and meta-analysis.** *BMJ Open.* 2019; 9(4): e026794.  
[PubMed Abstract](#) | [Free Full Text](#)
11. Rankin A, Cadogan CA, Patterson SM, *et al.*: **Interventions to improve the appropriate use of polypharmacy for older people.** *Cochrane Database Syst Rev.* 2018; 9(9): CD008165.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
12. Rankin A, Cadogan CA, Cooper J, *et al.*: **Interventions to improve the appropriate use of polypharmacy for older people: an updated Cochrane systematic review.** *International Journal of Pharmacy Practice.* 2018; 26(S1): 5–6.
13. Cadogan CA, Rankin A, Lewin S, *et al.*: **Application of the Intervention Complexity Assessment Tool for Systematic Reviews (iCAT\_SR) within a Cochrane review.** *Open Science Framework repository.* 2020.  
<http://www.doi.org/10.17605/OSF.IO/N3KW2>
14. Landis JR, Koch GG: **The measurement of observer agreement for categorical data.** *Biometrics.* 1977; 33(1): 159–74.  
[PubMed Abstract](#) | [Publisher Full Text](#)
15. Basger BJ, Moles RJ, Chen TF: **Impact of an enhanced pharmacy discharge service on prescribing appropriateness criteria: a randomised controlled trial.** *Int J Clin Pharm.* 2015; 37(6): 1194–205.  
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Bucci C, Jackevicius C, McFarlane K, *et al.*: **Pharmacist's contribution in a heart function clinic: patient perception and medication appropriateness.** *Can J Cardiol.* 2003; 19(4): 391–6.  
[PubMed Abstract](#)
17. Clyne B, Smith SM, Hughes CM, *et al.*: **Effectiveness of a Multifaceted Intervention for Potentially Inappropriate Prescribing in Older Patients in Primary Care: A Cluster-Randomized Controlled Trial (OPTI-SCRIPT Study).** *Ann Fam Med.* 2015; 13(6): 545–53.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
18. Crotty M, Rowett D, Spurling L, *et al.*: **Does the addition of a pharmacist transition coordinator improve evidence-based medication management and health outcomes in older adults moving from the hospital to a long-term care facility? Results of a randomized, controlled trial.** *Am J Geriatr Pharmacother.* 2004; 2(4): 257–64.  
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Dalleur O, Boland B, Losseau C, *et al.*: **Reduction of potentially inappropriate medications using the STOPP criteria in frail older inpatients: a randomised controlled study.** *Drugs Aging.* 2014; 31(4): 291–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Franchi C, Tettamanti M, Djade CD, *et al.*: **E-learning in order to improve drug prescription for hospitalized older patients: a cluster-randomized controlled study.** *Br J Clin Pharmacol.* 2016; 82(1): 53–63.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
21. Frankenthal D, Lerman Y, Kalendaryev E, *et al.*: **Intervention with the screening tool of older persons potentially inappropriate prescriptions/screening tool to alert doctors to right treatment criteria in elderly residents of a chronic geriatric facility: a randomized clinical trial.** *J Am Geriatr Soc.* 2014; 62(9): 1658–65.  
[PubMed Abstract](#) | [Publisher Full Text](#)
22. Gallagher PF, O'Connor MN, O'Mahony D: **Prevention of potentially inappropriate prescribing for elderly patients: a randomized controlled trial using STOPP/START criteria.** *Clin Pharmacol Ther.* 2011; 89(6): 845–54.  
[PubMed Abstract](#) | [Publisher Full Text](#)
23. Garcia-Gollarte F, Baleriola-Julvez J, Ferrero-Lopez I, *et al.*: **An educational intervention on drug use in nursing homes improves health outcomes resource utilization and reduces inappropriate drug prescription.** *J Am Med Dir Assoc.* 2014; 15(12): 885–91.  
[PubMed Abstract](#) | [Publisher Full Text](#)
24. Hanlon JT, Weinberger M, Samsa GP, *et al.*: **A randomized, controlled trial of a clinical pharmacist intervention to improve inappropriate prescribing in elderly outpatients with polypharmacy.** *Am J Med.* 1996; 100(4): 428–37.  
[PubMed Abstract](#) | [Publisher Full Text](#)
25. Michalek C, Wehling M, Schlitzer J, *et al.*: **Effects of "Fit FOR The Aged" (FORTA) on pharmacotherapy and clinical endpoints—a pilot randomized controlled study.** *Eur J Clin Pharmacol.* 2014; 70(10): 1261–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
26. Pitkälä KH, Juola AL, Kautiainen H, *et al.*: **Education to reduce potentially harmful medication use among residents of assisted living facilities: a randomized controlled trial.** *J Am Med Dir Assoc.* 2014; 15(12): 892–8.  
[PubMed Abstract](#) | [Publisher Full Text](#)
27. Schmader KE, Hanlon JT, Pieper CF, *et al.*: **Effects of geriatric evaluation and management on adverse drug reactions and suboptimal prescribing in the frail elderly.** *Am J Med.* 2004; 116(6): 394–401.  
[PubMed Abstract](#) | [Publisher Full Text](#)
28. Spinewine A, Swine C, Dhillon S, *et al.*: **Effect of a collaborative approach on the quality of prescribing for geriatric inpatients: a randomized, controlled trial.** *J Am Geriatr Soc.* 2007; 55(5): 658–65.  
[PubMed Abstract](#) | [Publisher Full Text](#)
29. Tamblin R, Huang A, Perreault R, *et al.*: **The medical office of the 21st century (MOXXI): effectiveness of computerized decision-making support in reducing inappropriate prescribing in primary care.** *CMAJ.* 2003; 169(6): 549–56.  
[PubMed Abstract](#) | [Free Full Text](#)
30. Taylor CT, Byrd DC, Krueger K: **Improving primary care in rural Alabama with a pharmacy initiative.** *Am J Health Syst Pharm.* 2003; 60(11): 1123–9.  
[PubMed Abstract](#) | [Publisher Full Text](#)
31. Trygstad TK, Christensen D, Garmise J, *et al.*: **Pharmacist response to alerts generated from Medicaid pharmacy claims in a long-term care setting: results from the North Carolina polypharmacy initiative.** *J Manag Care Pharm.* 2005; 11(7): 575–83.  
[PubMed Abstract](#) | [Publisher Full Text](#)
32. Trygstad TK, Christensen DB, Wegner SE, *et al.*: **Analysis of the North Carolina long-term care polypharmacy initiative: a multiple-cohort approach using propensity-score matching for both evaluation and targeting.** *Clin Ther.* 2009; 31(9): 2018–37.  
[PubMed Abstract](#) | [Publisher Full Text](#)
33. Wehling M, Burkhardt H, Kuhn-Thiel A, *et al.*: **VALFORTA: a randomised trial to validate the FORTA (Fit FOR The Aged) classification.** *Age Ageing.* 2016; 45(2): 262–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
34. Crotty M, Halbert J, Rowett D, *et al.*: **An outreach geriatric medication advisory service in residential aged care: a randomised controlled trial of case conferencing.** *Age Ageing.* 2004; 33(6): 612–7.  
[PubMed Abstract](#) | [Publisher Full Text](#)
35. Hanlon JT, Schmader KE, Samsa GP, *et al.*: **A method for assessing drug therapy appropriateness.** *J Clin Epidemiol.* 1992; 45(10): 1045–51.  
[PubMed Abstract](#) | [Publisher Full Text](#)
36. O'Mahony D, O'Sullivan D, Byrne S, *et al.*: **STOPP/START criteria for potentially inappropriate prescribing in older people: version 2.** *Age Ageing.* 2015; 44(2): 213–8.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
37. Hepler CD, Strand LM: **Opportunities and responsibilities in pharmaceutical care.** *Am J Hosp Pharm.* 1990; 47(3): 533–43.  
[PubMed Abstract](#)
38. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel: **American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults.** *J Am Geriatr Soc.* 2019; 67(4): 674–94.  
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Patterson SM, Hughes C, Kerse N, *et al.*: **Interventions to improve the appropriate use of polypharmacy for older people.** *Cochrane Database Syst Rev.* 2012; (5): CD008165.  
[PubMed Abstract](#) | [Publisher Full Text](#)
40. Atkins L, Francis J, Islam R, *et al.*: **A guide to using the Theoretical Domains Framework of behaviour change to investigate implementation problems.** *Implement Sci.* 2017; 12(1): 77.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
41. Peters G: **A practical guide to effective behavior change: How to identify what to change in the first place.** *European Health Psychologist.* 2014; 16(4): 142–55.  
[Reference Source](#)
42. Colquhoun HL, Brehaut JC, Sales A, *et al.*: **A systematic review of the use of theory in randomized controlled trials of audit and feedback.** *Implement Sci.* 2013; 8: 66.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
43. Davies P, Walker AE, Grimshaw JM: **A systematic review of the use of theory in the design of guideline dissemination and implementation strategies and interpretation of the results of rigorous evaluations.** *Implement Sci.* 2010; 5: 14.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
44. Michie S, Fixsen D, Grimshaw JM, *et al.*: **Specifying and reporting complex behaviour change interventions: the need for a scientific method.** *Implement Sci.* 2009; 4: 40.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
45. Colquhoun H, Michie S, Sales A, *et al.*: **Reporting and design elements of audit and feedback interventions: a secondary review.** *BMJ Qual Saf.* 2017; 26(1): 54–60.  
[PubMed Abstract](#) | [Publisher Full Text](#)
46. Harper R, Lewin S, Glenton C, *et al.*: **Completeness of reporting of setting and health worker cadre among trials on antenatal iron and folic acid supplementation in pregnancy: an assessment based on two Cochrane reviews.** *Syst Rev.* 2013; 2: 42.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

47. Shepperd S, Lewin S, Straus S, *et al.*: **Can we systematically review studies that evaluate complex interventions?** *PLoS Med.* 2009; 6(8): e1000086.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
48. Möhler R, Köpke S, Meyer G: **Criteria for Reporting the Development and Evaluation of Complex Interventions in healthcare: revised guideline (CReDECI 2).** *Trials.* 2015; 16: 204.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
49. Hoffmann TC, Glasziou PP, Boutron I, *et al.*: **Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide.** *BMJ.* 2014; 348: g1687.  
[PubMed Abstract](#) | [Publisher Full Text](#)
50. Albrecht L, Archibald M, Arseneau D, *et al.*: **Development of a checklist to assess the quality of reporting of knowledge translation interventions using the Workgroup for Intervention Development and Evaluation Research (WIDER) recommendations.** *Implement Sci.* 2013; 8: 52.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
51. Guise JM, Butler ME, Chang C, *et al.*: **AHRQ series on complex intervention systematic reviews-paper 6: PRISMA-CI extension statement and checklist.** *J Clin Epidemiol.* 2017; 90: 43–50.  
[PubMed Abstract](#) | [Publisher Full Text](#)
52. Petticrew M: **Time to rethink the systematic review catechism? Moving from 'what works' to 'what happens'.** *Syst Rev.* 2015; 4: 36.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
53. Kelly MP, Noyes J, Kane RL, *et al.*: **AHRQ series on complex intervention systematic reviews-paper 2: defining complexity, formulating scope, and questions.** *J Clin Epidemiol.* 2017; 90: 11–18.  
[PubMed Abstract](#) | [Publisher Full Text](#)
54. Jones RA, Blackburn NE, Woods C, *et al.*: **Interventions promoting active transport to school in children: A systematic review and meta-analysis.** *Prev Med.* 2019; 123: 232–41.  
[PubMed Abstract](#) | [Publisher Full Text](#)
55. Squires JE, Sullivan K, Eccles MP, *et al.*: **Are multifaceted interventions more effective than single-component interventions in changing health-care professionals' behaviours? An overview of systematic reviews.** *Implement Sci.* 2014; 9: 152.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
56. Petticrew M, Anderson L, Elder R, *et al.*: **Complex interventions and their implications for systematic reviews: a pragmatic approach.** *J Clin Epidemiol.* 2013; 66(11): 1209–14.  
[PubMed Abstract](#) | [Publisher Full Text](#)
57. Guise JM, Chang C, Butler M, *et al.*: **AHRQ series on complex intervention systematic reviews-paper 1: an introduction to a series of articles that provide guidance and tools for reviews of complex interventions.** *J Clin Epidemiol.* 2017; 90: 6–10.  
[PubMed Abstract](#) | [Publisher Full Text](#)
58. Greenhalgh T, Papoutsi C: **Studying complexity in health services research: desperately seeking an overdue paradigm shift.** *BMC Med.* 2018; 16(1): 95.  
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

# Open Peer Review

Current Peer Review Status:   

---

## Version 1

Reviewer Report 02 July 2020

<https://doi.org/10.21956/hrbopenres.14140.r27477>

© 2020 Ribeiro D. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Daniel Cury Ribeiro** 

School of Physiotherapy, University of Otago, Dunedin, New Zealand

Thank you for inviting me to review this interesting case study. The study aimed to apply the iCAT\_SR to a subset of studies that were recently included in a Cochrane Review that assessed interventions designed to improve appropriate polypharmacy in the elderly. Authors independently assessed included studies using the iCAT\_SR, assessed and reported the inter-rater reliability using the Cohen's Kappa coefficient. The findings suggest limited consistency in intervention complexity across included studies and, importantly, highlight the lack of information within included studies. In the conclusions, the authors highlight the need for more detailed information regarding the interventions tested by original studies, the context and causal pathways through which interventions may work.

This is an interesting and well-written study. I enjoyed reading it and I have only one minor suggestion for the authors. I hope these are useful for improving the quality of the reporting.

Table 3: suggest adding a caption below the table, for defining what "high, intermediate and low" refer to. This is implied but it is not explicit.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Process evaluation of clinical trials.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 22 June 2020

<https://doi.org/10.21956/hrbopenres.14140.r27475>

© 2020 Gaarder M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

**Marie Gaarder**

International Initiative for Impact Evaluation, Oslo, Norway

The aim of the study was to test the Complexity Assessment Tool for Systematic Reviews (iCAT\_SR) in a subset of studies included in a Cochrane review in order to promote its use and refinement. In order to draw the right conclusions and make the right interpretations of review findings, it is important to understand and document the implementation details and the context in which interventions take place. Hence testing the extent to which the tool can be implemented and whether it adds value is important.

Interventions were assessed using the six core iCAT\_SR dimensions: (1) 'Target organisational levels/categories'; (2) 'Target behaviour/actions'; (3) 'Active intervention components'; (4) 'Degree of tailoring'; (5) 'Level of skill required by intervention deliverers'; (6) 'Level of skill required by intervention recipients'. Attempts were made to apply four optional dimensions: 'Interaction between intervention components'; 'Context/setting'; 'Recipient/provider factors'; 'Nature of causal pathway'.

I have three comments:

1. As I have argued elsewhere (blog: [www.3ieimpact.org/blogs/misdiagnosis-and-evidence-trap-tale-inadequate-program-design](http://www.3ieimpact.org/blogs/misdiagnosis-and-evidence-trap-tale-inadequate-program-design)), identifying the root cause or causes of a problem is maybe the most important step to designing the correct interventions to treat it. This may be obvious but is done quite infrequently, certainly in sectors outside of medicine, and I assume the iCAT\_SR is meant for wider use. What this means is that you could have two identically designed (complex) interventions focusing on the same issue, in this case aimed at improving appropriate polypharmacy in older people, yet one works and the other does not because the underlying reasons for suboptimal polypharmacy were different. I do not think that the 6 SR dimensions, even if they could be applied easily, would hence be sufficient to make the right interpretations of review findings.
2. The additional four dimensions focused on interaction, context, causal pathway etc are also all key to understanding the underlying factors that drive the current situation and the effectiveness of the

intervention. It is not clear whether they directly incorporate the questions of the existence of in-depth diagnoses of the problem/root cause(s) but I would strongly recommend that they should and that this should be elevated to a separate dimension. Also, the study should explain why it was decided to add the four dimensions. They seem key (from a theoretical perspective) and it is surprising that they had not been considered among the original dimensions.

3. Given the finding that there was not sufficient information on the additional dimensions to report on these, and the fact that the first 6 dimensions are necessary but not sufficient to explain differences in effectiveness, I am surprised at the section on refinements. I would venture that the authors should go further in indicating that the tool needs to incorporate the spirit behind the additional dimensions, namely understanding context, root causes, causal pathways etc.

Congratulations to the authors for a very valuable contribution.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Not applicable

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** International development - impact evaluations, organizational evaluations and systematic reviews.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

Reviewer Report 15 June 2020

<https://doi.org/10.21956/hrbopenres.14140.r27476>

© 2020 Puljak L. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



**Livia Puljak** 

Center for Evidence-Based Medicine and Health Care, Catholic University of Croatia, Zagreb, Croatia

I have reviewed the manuscript titled “Application of the intervention Complexity Assessment Tool for Systematic Reviews within a Cochrane review: an illustrative case study”. The aim of this case study was to apply the iCAT\_SR to a subset of 20 studies included in a Cochrane review of interventions aimed at improving appropriate polypharmacy in older people.

My comments are as follows:

- This sample of 20 studies is rather small, and homogeneous in terms of the chosen topic. But this was a case study, so that is acceptable.
- In the abstract, it is unclear what does it mean limited consistency in intervention complexity, and whether this consistency is desired or not.
- It is commendable that there are additional details posted on OSF as supplementary files.
- I am impressed that none of the assessments in Table 3 are “unclear”. I would expect poorer reporting.
- It is acknowledged that this work is not intended as a definitive assessment of intervention complexity in this field of research but as proof of concept of the iCAT\_SR’s application.
- It would be interesting to report inter-rater agreement for each individual iCAT\_SR dimension.

**Is the work clearly and accurately presented and does it cite the current literature?**

Yes

**Is the study design appropriate and is the work technically sound?**

Yes

**Are sufficient details of methods and analysis provided to allow replication by others?**

Yes

**If applicable, is the statistical analysis and its interpretation appropriate?**

Yes

**Are all the source data underlying the results available to ensure full reproducibility?**

Yes

**Are the conclusions drawn adequately supported by the results?**

Yes

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Research methodology.

**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.**

